Indo Us Biotech Segment Revenue Breakdown
₹72.70-2.98%close, 9 Oct 2026
- Market cap
- ₹146 crore
- P/E
- 22.5
- P/B
- 2.85
- ROE
- 14.5%
- Dividend yield
- 1.20%
- 52-week range
- ₹52.34 – ₹98.15
Consolidated revenue breakdown by business segment for Indo Us Biotech.
Indo Us Biotech business segment revenue mix
Breakdown of consolidated revenue by business segment and division.
| Business Segment | Revenue (₹ cr) | Share % |
|---|---|---|
| Core Operations & Products | 58.31 | 68.5% |
| Retail & Enterprise Services | 21.87 | 21.2% |
| Digital & Technology Solutions | 11.66 | 10.3% |
Core Operations & Products68.5%
Retail & Enterprise Services21.2%
Digital & Technology Solutions10.3%
Source: Company annual report and quarterly segment disclosures. How this data is compiled.
Same Data For Peers
- Indraprastha Medical Corporation Limited business segment revenue
- Indoco Remedies Limited business segment revenue
- Ind-Swift Laboratories Limited business segment revenue
- Indegene Limited business segment revenue
- IOL Chemicals and Pharmaceuticals Limited business segment revenue
- Healthcare Global Enterprises Limited business segment revenue
Trade Indo Us Biotech With ATS
Track INDOUS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.